Incannex Healthcare Ltd - ESG Rating & Company Profile powered by AI
Scroll down to the bottom of the webpage for potential risks for Incannex Healthcare Ltd based on sector, location and marketcap. If you work at Incannex Healthcare Ltd and you wish to licence your ESG rating, please get in touch. Comprehensive ESG assessment of Incannex Healthcare Ltd can be reached by registering for free.
Incannex Healthcare Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.1; made up of an environmental score of 4.0, social score of 6.4 and governance score of 8.0.
6.1
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
450 | Valneva USA Inc | 6.2 | High |
450 | Sino Biopharmaceutical Ltd | 6.2 | High |
483 | Incannex Healthcare Ltd | 6.1 | High |
483 | Bora Pharmaceuticals Co Ltd | 6.1 | High |
483 | Affimed NV | 6.1 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Incannex Healthcare Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Incannex Healthcare Ltd disclose current and historical energy intensity?
Does Incannex Healthcare Ltd report the average age of the workforce?
Does Incannex Healthcare Ltd reference operational or capital allocation in relation to climate change?
Does Incannex Healthcare Ltd disclose its ethnicity pay gap?
Does Incannex Healthcare Ltd disclose cybersecurity risks?
Does Incannex Healthcare Ltd offer flexible work?
Does Incannex Healthcare Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Incannex Healthcare Ltd disclose the number of employees in R&D functions?
Does Incannex Healthcare Ltd conduct supply chain audits?
Does Incannex Healthcare Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Incannex Healthcare Ltd conduct 360 degree staff reviews?
Does Incannex Healthcare Ltd disclose the individual responsible for D&I?
Does Incannex Healthcare Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Incannex Healthcare Ltd disclose current and / or historical scope 2 emissions?
Does Incannex Healthcare Ltd disclose water use targets?
Does Incannex Healthcare Ltd have careers partnerships with academic institutions?
Did Incannex Healthcare Ltd have a product recall in the last two years?
Does Incannex Healthcare Ltd disclose incidents of discrimination?
Does Incannex Healthcare Ltd allow for Work Councils/Collective Agreements to be formed?
Has Incannex Healthcare Ltd issued a profit warning in the past 24 months?
Does Incannex Healthcare Ltd disclose parental leave metrics?
Does Incannex Healthcare Ltd disclose climate scenario or pathway analysis?
Does Incannex Healthcare Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Incannex Healthcare Ltd disclose the pay ratio of women to men?
Does Incannex Healthcare Ltd support suppliers with sustainability related research and development?
Does Incannex Healthcare Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Incannex Healthcare Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Incannex Healthcare Ltd involved in embryonic stem cell research?
Does Incannex Healthcare Ltd disclose GHG and Air Emissions intensity?
Does Incannex Healthcare Ltd disclose its waste policy?
Does Incannex Healthcare Ltd report according to TCFD requirements?
Does Incannex Healthcare Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Incannex Healthcare Ltd disclose energy use targets?
Does Incannex Healthcare Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Incannex Healthcare Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Incannex Healthcare Ltd
These potential risks are based on the size, segment and geographies of the company.
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury/concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.